ChipDX LLC Information

ChipDX develops and delivers novel multi-gene diagnostic and prognostic assays for oncology. The aim of the company is to increase access to advanced, well-validated predictive and prognostic assays, through collaborations with existing diagnostic service providers and also through our modular, online delivery system: www.ChipDX.com Currently we have created tests for: - Assessing the quality of a patients genomic profile to ensure reliable, accurate results - Characterizing metastatic or poorly differentiated tumors, and - Predicting recurrence in patients diagnosed with early stage breast or colon cancer. Other novel assays are in active development and we are keen to form strategic collaborations with appropriate organizations and individuals to further validate and market those already developed. Related publications: Van Laar, R.K., An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Br J Cancer. Van Laar, R. K. (In Press). "Design and multi-series validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival." J Mol Diagn.